Lemonade Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Lemonade Inc trades at $53.08 (market cap $4.08B), while Regeneron Pharmaceuticals Inc trades at $796.39 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 20.4× Lemonade Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals.
| LMND | REGN | |
|---|---|---|
Market Cap | $4.08B | $83.19B |
Sector | Financials | Health |
52-Week High | $96.57 | $812.27 |
52-Week Low | $47.38 | $555.51 |
Enterprise Value | $3.94B | $77.90B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $52.94, up 2.08% today, with a bearish technical signal from moving averages despite recent earnings beats. Revenue growth is strong at 79% year-over-year in Q2 2026, but profitability remains elusive with a net income margin of -14.19% in 2025. The company targets positive adjusted EBITDA by Q4 2026, supported by expanding insurance offerings in states like Nebraska and Maine.
The outlook is mixed: accelerating premium growth and path to profitability offer upside, but high valuation (P/S of 4.11) and persistent losses pose risks. Analyst consensus is evenly split, with a $58 price target suggesting modest upside from current levels, though technical resistance near $54 may limit near-term gains.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →